120 related articles for article (PubMed ID: 20197486)
1. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
Liu F; Vessey L; Wenning L; Connolly S; Buckland M; Johnson-Levonas AO; Denker A; Wagner JA; Lai E
J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
[TBL] [Abstract][Full Text] [Related]
2. Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.
Schwartz JI; Stroh M; Gao B; Liu F; Rosko K; Zajic S; Meehan AJ; Ruckle J; Lai E; Wagner JA
Cardiovasc Ther; 2009; 27(4):239-45. PubMed ID: 19903187
[TBL] [Abstract][Full Text] [Related]
3. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
[TBL] [Abstract][Full Text] [Related]
4. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.
Stroh M; Wenning L; Luo WL; Desai R; Bi S; Keshavarz S; Lazarus N; Lunde NM; Smith WB; Schwartz M; Stone J; Wagner J; Lai E; Dishy V
Am J Ther; 2009; 16(5):379-84. PubMed ID: 19433974
[TBL] [Abstract][Full Text] [Related]
6. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
Denker AE; Morelli G; Vessey LK; Li S; Yuan J; Dunbar S; Lewis NM; Taggart W; Wagner JA
Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
[TBL] [Abstract][Full Text] [Related]
8. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.
Vaz da Silva M; Costa R; Soares E; Maia J; Falcão A; Almeida L; Soares da Silva P
Fundam Clin Pharmacol; 2009 Aug; 23(4):509-14. PubMed ID: 19500154
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
Lai E; Wenning LA; Crumley TM; De Lepeleire I; Liu F; de Hoon JN; Van Hecken A; Depré M; Hilliard D; Greenberg H; O'Neill G; Metters K; Gottesdiener KG; Wagner JA
Clin Pharmacol Ther; 2008 Jun; 83(6):840-7. PubMed ID: 17882161
[TBL] [Abstract][Full Text] [Related]
10. Absence of a clinically relevant interaction between etanercept and digoxin.
Zhou H; Parks V; Patat A; Le Coz F; Simcoe D; Korth-Bradley J
J Clin Pharmacol; 2004 Nov; 44(11):1244-51. PubMed ID: 15496642
[TBL] [Abstract][Full Text] [Related]
11. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
Luo WL; Crumley T; Ebel D; Atiee GJ; Royalty J; Johnson-Levonas AO; Wagner J; Lai E
J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
[TBL] [Abstract][Full Text] [Related]
12. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Lauring B; Dishy V; Luo WL; Laterza O; Patterson J; Cote J; Chao A; Larson P; Gutierrez M; Wagner JA; Lai E
J Clin Pharmacol; 2009 Dec; 49(12):1426-35. PubMed ID: 19833861
[TBL] [Abstract][Full Text] [Related]
13. Absence of an interaction between tigecycline and digoxin in healthy men.
Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
[TBL] [Abstract][Full Text] [Related]
14. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
Smulders RA; Kuipers ME; Krauwinkel WJ
Br J Clin Pharmacol; 2006 Aug; 62(2):210-7. PubMed ID: 16842396
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers.
Kim TE; Kim BH; Kim J; Kim KP; Yi S; Shin HS; Lee YO; Lee KH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Oct; 31(10):2249-57. PubMed ID: 19922896
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction of sparfloxacin and digoxin.
Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH
Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
Darwish M; Chang S; Hellriegel ET
Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
[TBL] [Abstract][Full Text] [Related]
18. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
19. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
[TBL] [Abstract][Full Text] [Related]
20. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
